BRAVNETSA Drug Patent Profile
When do Bravnetsa patents expire, and what generic alternatives are available?
Bravnetsa is a drug marketed by Lantheus Medical and is included in one NDA.
The generic ingredient in BRAVNETSA is lutetium lu-177 dotatate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the lutetium lu-177 dotatate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BRAVNETSA?
- What are the global sales for BRAVNETSA?
- What is Average Wholesale Price for BRAVNETSA?
Summary for BRAVNETSA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | BRAVNETSA at DailyMed |
US Patents and Regulatory Information for BRAVNETSA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medical | BRAVNETSA | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 217060-001 | Sep 21, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

